|
UBR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.78794781599845E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.09509995200364E-09 |
| Normal-vs-Stage2 |
1.67047999999337E-05 |
| Normal-vs-Stage3 |
8.17013123821653E-13 |
| Normal-vs-Stage4 |
2.9367952514292E-11 |
| Stage1-vs-Stage2 |
8.507200E-01 |
| Stage1-vs-Stage3 |
9.298500E-03 |
| Stage1-vs-Stage4 |
3.095100E-03 |
| Stage2-vs-Stage3 |
9.906100E-02 |
| Stage2-vs-Stage4 |
6.391900E-02 |
| Stage3-vs-Stage4 |
6.269200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.34998695450395E-12 |
| Normal-vs-AfricanAmerican |
6.622300E-04 |
| Normal-vs-Asian |
2.16120000007258E-07 |
| Caucasian-vs-AfricanAmerican |
3.671400E-01 |
| Caucasian-vs-Asian |
8.661800E-01 |
| AfricanAmerican-vs-Asian |
3.656800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.17149631609459E-11 |
| Normal-vs-Female |
8.24810220123595E-11 |
| Male-vs-Female |
1.620550E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11430000004908E-07 |
| Normal-vs-Age(41-60Yrs) |
1.59310342695562E-11 |
| Normal-vs-Age(61-80Yrs) |
7.72939490190083E-11 |
| Normal-vs-Age(81-100Yrs) |
1.736200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.010600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.902200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.821200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.318000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.853600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.683600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.023700E-02 |
| Classical-VS-Follicular |
4.133000E-01 |
| Classical-VS-Other |
1.242630E-01 |
| Classical-VS-Normal |
4.74290051677428E-10 |
| Tall-VS-Follicular |
1.132180E-01 |
| Tall-VS-Other |
6.190400E-01 |
| Tall-VS-Normal |
2.01950001166296E-09 |
| Follicular-VS-Other |
2.859800E-01 |
| Follicular-VS-Normal |
1.85640000038845E-07 |
| Other-VS-Normal |
4.237400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.21220034010605E-10 |
| Normal-vs-N1 |
2.59819998849053E-09 |
| N0-vs-N1 |
2.723800E-01 |
|
|
